Organization
Replimune, Inc.
2 abstracts
Abstract
An open-label, multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.Org: Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Replimune, Inc., Clinical Cooperation Unit Virotherapy, German Cancer Center Research Center (DKFZ),
Abstract
A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec (VO) combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).Org: UPMC Hillman Cancer Center, Pittsburgh, PA, Replimune, Inc., Woburn, MA, Gustave Roussy and Paris-Saclay University,